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Abstract 
Adoptive transfer of T-cells engineered with a cancer specific T-cell receptor (TCR) have 
demonstrated clinical benefit. However, the risk for off-target toxicity of TCRs remains a 
concern. 
Here, we examined the cross-reactive profile of T-cell clone (7B5) with a high functional 
sensitivity for the hematopoietic-restricted minor histocompatibility antigen HA-2 in the context 
of HLA-A*02:01. HA-2
pos
 EBV-LCLs and primary acute myeloid leukemia samples, but not 
hematopoietic HA-2
neg
 samples, are effectively recognized. However, we found unexpected off-
target recognition of human fibroblasts and keratinocytes not expressing the HA-2 antigen.  
To uncover the origin of this off-target recognition we performed an alanine scanning approach, 
identifying 6 out of 9 positions to be important for peptide recognition. This indicates a low risk 
for broad cross-reactivity. However, using a combinatorial peptide library scanning approach, we 
identified a CDH13 derived peptide activating the 7B5 T-cell clone. This was confirmed by 
recognition of CDH13-transduced EBV-LCLs and cell subsets endogenously expressing CDH13, 
such as proximal tubular epithelial cells. 
As such, we recommend the use of a combinatorial peptide library scan followed by screening 
against additional cell subsets to validate TCR specificity and detect off-target toxicity due to 
cross-reactivity directed against unrelated peptides before selecting candidate TCRs for clinical 
testing. 
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Introduction 
Immunotherapy has obtained a prominent role in the field of oncology and has proven valuable 
in the treatment of different types of tumors. A range of immunotherapies are under 
development, varying from chimeric antigen receptors (CARs)
1
, expanding tumor infiltrating 
lymphocytes (TILs)
2, 3
 and TCR transduced effector cells
4, 5
. Various studies successfully make 
use of TCR-engineered T-cells to enhance patients adaptive immune responses against 
malignancies, demonstrating potent anti-tumor reactivity
6-9
. 
No matter how promising therapies using TCR-engineered T-cells may be, they come with side 
effects and risks. T-cells are naturally checked for recognition of self-peptides in the context of 
self-HLA and deleted in the thymus if this recognition is too strong, in a process called negative 
selection
10
. This selection process is absent or non-optimal when TCRs are derived from donors 
with mismatched HLA-typing, when they are isolated from humanized mouse models expressing 
only one HLA molecule and no human proteins, or when TCRs are structurally altered for 
affinity enhancement
11, 12
. 
Affinity enhancement of TCRs can result in both on- and off-target toxicity
13
. Recent examples 
of clinically tested TCRs directed against MAGE-A3 and MART-1 demonstrated severe 
toxicities
12, 14-17
. In the clinical trial testing a modified anti-MAGE-A3 TCR, derived from 
immunization of HLA-A*02:01 transgenic mice, 2 out of 9 cancer patients developed fatal on-
target neurological toxicity, due to recognition of a peptide derived from the same gene-family 
which is expressed in the brain
15
. In another trial, where an affinity enhanced anti-MAGE-A3 
TCR was tested in myeloma and melanoma patients, 2 patients died due to off-target toxicity 
caused by recognition of a completely different peptide, resulting in severe myocardial damage
12, 
17
. These clinical cases show how difficult it is to predict the exact specificity and the resulting 
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effects of TCRs that did not undergo optimal thymic selection. It is crucial to develop strategies 
to extensively validate the exact specificity of TCRs, particularly since TCR-engineered T-cells 
are highly sensitive
14, 18
. 
In this study, we aimed to develop a reliable screening pipeline for early detection of off-target 
toxicity due to the cross-reactivity of TCRs directed against unrelated peptides. In previous 
work, we have focused on the identification of therapeutic TCRs directed against hematopoietic 
restricted minor histocompatibility antigens (MiHA) for the treatment of hematological 
malignancies. The HLA-A*02:01 restricted HA-2 peptide YIGEVLVSV is a well-known 
example of such a MiHA
19, 20
. In recent experiments we isolated a HA-2 specific T-cell clone, 
7B5, using an in vitro HLA-mismatched setting. We validated its specificity for the HA-2 
antigen in hematopoietic cell subsets. However, we found unexpected off-target recognition of 
human fibroblasts not expressing the HA-2 antigen, raising the questions what triggered this 
activation and what method is suitable to examine this. Thus, we investigated the off-target 
cross-reactive potential of this high avidity T-cell clone using different screening methods and 
characterized its fine specificity. 
Currently, an amino acid scanning approach is the recommended method
21
, which we compared 
to screening with a 9-mer combinatorial peptide library (CPL)
22
. To validate recognition of 
predicted cross-reactive target peptides by the 7B5 T-cell clone, as discovered by the different 
screening approaches, we then screened the 7B5 T-cell clone against several non-hematopoietic 
cell subsets endogenously expressing these peptides. As a control, we used a HA-2 specific T-
cell clone, HA2.27, previously isolated from a chronic myeloid leukemia patient that 
experienced a Graft versus Leukemia (GvL) response after HLA-matched SCT and subsequent 
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donor lymphocyte infusion (DLI)
23
. The patient from whom these clones were isolated did not 
experience any harmful GvHD
24
 and no ex vivo cross-reactivity was discovered. 
We show that the amino acid scanning approach alone provided useful information about which 
amino acid (AA) positions in the peptide are important for TCR recognition, but its ability to 
elucidate the cross-reactivity profile of the 7B5 TCR was limited. Instead, we were able to detect 
off-target reactivity directed against a peptide derived from CDH13 using a CPL scanning 
approach. This was confirmed with CDH13 transduced HA-2
neg
 EBV-LCLs and the potential in 
vivo consequences were deduced by screening against a broad range of different cell subsets. 
 
Results 
Identification of a HA-2 specific T-cell clone from the allogeneic TCR repertoire 
T-cell clones from an HLA-A*02:01
neg
 individual were isolated using pMHC-tetramers 
composed of the HA-2 peptide bound to HLA-A*02:01. pMHC-tetramer
pos
 cells were first 
enriched by magnetic-activated cell sorting (MACS) followed by single-cell sorting of pMHC-
tetramer
pos
 CD8
pos
 T-cells. T-cell clones were selected that demonstrated reactivity against T2 
cells loaded with the HA-2 peptide but not against unloaded T2 cells. Among these T-cell clones, 
clone 7B5 demonstrated the highest functional sensitivity when stimulated with titrated amounts 
of HA-2 peptide. This reactivity was comparable to the patient derived control clone HA2.27, 
that was isolated from a beneficial GVL response after allogeneic stem cell transplantation 
(SCT) and subsequent DLI (Figure 1A). 
Specific binding to the APC-labeled HA-2 pMHC-tetramer was validated for both T-cell clones. 
Both the 7B5 T-cell clone and the HA2.27 T-cell clone showed specific staining with the APC-
labeled HA-2 pMHC-tetramer with similar intensity (Figure 1B). 
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Expression of the MYO1G gene, encoding for the MiHA HA-2, is restricted to hematopoietic 
tissues
20
. We confirmed this restricted expression in an in-house generated microarray gene 
expression database (Supplementary Figure 1)
25
. To investigate whether T-cell clone 7B5 was 
able to selectively recognize cell subsets expressing HA-2 we tested the HA-2 reactive T-cell 
clones against different hematopoietic cell subsets, starting with SNP-genotyped EBV-LCLs that 
were either positive or negative for the MiHA HA-2. Robust recognition of HLA-A*02:01
pos
 
HA-2
pos
 EBV-LCLs, but not HLA-A*02:01
pos
 HA-2
neg
 or HLA-A*02:01
neg
 EBV-LCLs was 
detected, which was comparable to the HA2.27 T-cell clone (Figure 2A). In addition, the anti-
tumor reactivity of T-cell clone 7B5 was tested against different HLA-A*02:01
pos
 primary AML 
samples either positive or negative for the MiHA HA-2. HLA-A*02:01
pos
 fibroblasts and HLA-
A*02:01
pos
 keratinocytes were included as HA-2
neg
 controls. HA-2
pos
 AML samples were 
similarly recognized by both the HA2.27 T-cell clone and the 7B5 T-cell clone, whereas the HA-
2
neg
 AML sample was not (Figure 2B). However, the HLA-A*02:01
pos
 HA-2
neg
 fibroblasts and 
keratinocytes that were not recognized by the HA2.27 T-cell clone as expected, were efficiently 
recognized by the 7B5 T-cell clone (Figure 2B). 
All these results indicate that the 7B5 T-cell clone is a high avidity T-cell clone, capable of 
targeting HA-2 expressing hematopoietic cell subsets in the context of HLA-A*02:01. 
Unexpectedly, the 7B5 T-cell clone recognized HLA-A*02:01
pos 
HA-2
neg
 human fibroblasts and 
keratinocytes as well. 
 
Analysis of off-target cross-reactivity of the 7B5 T-cell clone 
We showed that the 7B5 T-cell clone and the HA2.27 T-cell clone have a similar functional 
sensitivity for HA-2, but the 7B5 T-cell clone demonstrated cross-reactivity against HA-2
neg
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fibroblasts and keratinocytes. In order to assess what causes this off-target recognition of 
fibroblasts and keratinocytes we used an alanine scanning approach. Both HA-2 reactive clones 
were tested against the immunogenic HA-2 sequence (YIGEVLVSV), the naturally occurring 
non-immunogenic counterpart (YIGEVLVSM), and newly synthesized HA-2 peptides in which 
every AA is sequentially replaced by an alanine (A). In Table 1 the different peptides are 
summarized. According to NetMHC4.0 none of the alanine substitutions interfere with HLA-
A*02:01 binding to a relevant extent. Both HA-2 T-cell clones were incubated overnight with 
peptide-pulsed T2 cells at different concentrations (8 nM, 40 nM and 200 nM), and IFN-y 
production was measured. When alanine substitution resulted in a substantial decrease in IFN-y 
production compared to the immunogenic HA-2 sequence, this position was considered essential. 
The results, depicted in Figure 3A-C, demonstrate that for T-cell clone 7B5 positions 2, 3, 4, 5, 6 
and 7 were important for HA-2 specific recognition. This recognition pattern was slightly 
different from the HA-2.27 clone, since for this clone positions 1, 2, 3, 4, and 6 were important 
for HA-2 specific recognition. 
For the 7B5 T-cell clone an in silico search was carried out to identify protein sequences that 
contain the motif X-I-G-E-V-L-V-X-X. We searched for human self-protein derived peptide 
sequences with this motif using the ScanProsite webtool. Besides the HA-2 peptide, this search 
resulted in only one other peptide sequence PIGEVLVSS derived from the human gene KLF6. 
However, this KLF6 derived sequence was not predicted to bind HLA-A*02:01 according to 
NetMHC4.0, thus we concluded that there was a low risk of cross-reactivity, based on this amino 
acid scanning approach. 
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Next we performed a 9-mer combinatorial peptide library (CPL) scan. This CPL is composed of 
180 different 9-mer peptide mixtures. In every peptide mixture one AA position has a fixed L-
amino acid residue, but all other positions are degenerate enabling incorporation of any 1 of 19 
natural L-amino acids in all remaining 8 positions (cysteine is excluded). The 7B5 T-cell clone 
was incubated overnight with T2 cells pulsed with the 180 different peptide mixtures and IFN-y 
production was measured. Results are depicted in a heatmap (Figure 4). Using the WSBC PI 
CPL webtool, we conducted a 9-mer CPL-driven search of the human self-protein database to 
produce a list of the top 100 peptide sequences ranked in order of likelihood of recognition 
(Supplementary Table 1). After removing duplicate sequences a list of 42 peptide sequences 
remained and further refined on the basis of whether they were predicted to bind HLA-A*02:01 
using NetMHC4.0. This resulted in a final list of 10 peptide sequences which were subsequently 
synthesized (Table 2). The ability of the T-cell clones 7B5 and HA2.27 to recognize these 
candidate peptides was determined by measuring the IFN-y production after stimulation with T2 
cells loaded with titrated concentrations of these peptides. Only one peptide, the CDH13 derived 
peptide (p01) SVGSVLLTV, was recognized with a similar sensitivity as the HA-2 peptide (p02) 
(Figure 5A). The patient derived HA2.27 control clone did not recognize any other peptide but 
HA-2 (Figure 5B). 
In order to confirm processing and presentation of the CDH13 derived peptide in HLA-A*02:01, 
we transduced CDH13 into two different HLA-A*02:01
pos
 HA-2
neg
 EBV-LCLs (IZA and HRK). 
Recognition of the transduced and untransduced EBV-LCLs was evaluated by IFN-y ELISA. 
The 7B5 T-cell clone did not recognize untransduced HLA-A*02:01
pos
 HA-2
neg
 EBV-LCLs, 
similar to the HA2.27 T-cell clone, but CDH13 transduced HLA-A*02:01
pos
 HA-2
neg
 EBV-LCLs 
were highly recognized by the 7B5 T-cell clone, whereas the HA2.27 T-cell clone was not able 
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to recognize these transduced EBV-LCLs (Figure 5C). These results demonstrate that T-cell 
clone 7B5 is cross-reactive against the CDH13 derived peptide. 
 
Cross-reactivity directed against CDH13 
We showed that T-cell clone 7B5 is cross-reactive towards a CDH13 derived peptide which is 
presented by HLA-A*02:01. Next, we wanted to investigate the possible implications of this 
cross-reactivity in vivo. According to our gene expression microarray database
25
, the CDH13 
gene is expressed by a wide variety of healthy non-hematopoietic cell subsets, e.g. fibroblasts, 
keratinocytes, proximal tubular epithelial cells and melanoma cell line FM6 (Supplementary 
Figure 2). We tested the 7B5 T-cell clone against keratinocytes and fibroblasts derived from 
HLA-A*02:01
pos
 donors, either untreated or pretreated with IFN-y for 2 days to upregulate HLA 
expression, and HLA-A*02:01
pos
 proximal tubular epithelial cells and melanoma cell line FM6. 
All cell-subsets were recognized by the 7B5 T-cell clone, but not by the HA2.27 T-cell clone 
(Figure 6). To confirm that only HLA-A*02:01 restricted epitopes were recognized, we included 
HLA-A*02:01
neg
 fibroblasts, either untreated or pretreated with IFN-y for 2 days. The HLA-
A*02:01
neg
 fibroblasts were unable to activate the 7B5 T-cell clone (Figure 6). 
All these results demonstrate that the 7B5 T-cell clone can activate in response to both the HA-2 
antigen and the CDH13 derived peptide SVGSVLLTV, causing cross-reactivity restricted to 
HLA-A*02:01
pos
 tissues. 
 
Discussion 
In this study, we detected off-target reactivity of the 7B5 TCR directed against a peptide derived 
from the gene CDH13 using a CPL scanning approach, which was confirmed by the ability of 
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the 7B5 T-cell clone to recognize CDH13 transduced HA-2
neg
 EBV-LCLs and several cell 
subsets endogenously expressing CDH13. We show that the standard alanine scanning approach 
alone provided useful information about which AA positions in the peptide are important for 
TCR recognition, but its ability to elucidate cross-reactivity for the 7B5 TCR was limited. 
The 7B5 T-cell clone was isolated from a HLA-A*02:01 negative donor, thus due to the HLA-
mismatched experimental setting, thymic selection did not occur. The 7B5 T-cell clone 
recognizes the hematopoietic restricted minor histocompatibility antigen (MiHA) HA-2 in the 
context of HLA-A*02:01. The 7B5 T-cell clone was shown to have a functional sensitivity that 
was similar to the patient derived T-cell clone HA2.27, as concentrations below 1nM of HA-2 
peptide loaded on T2 cells could still trigger IFN-y production. Also endogenously processed 
and presented HA-2 peptide was effectively recognized by the 7B5 T-cell clone, as indicated by 
IFN-y production upon incubation with HA-2
pos
 EBV-LCLs and primary AML samples. Results 
were similar to the HA2.27 T-cell clone and no recognition of HA-2
neg
 EBV-LCLs or primary 
AML samples was observed. 
The results of the alanine scanning approach suggested a low risk for broad cross-reactivity of 
the 7B5 T-cell clone, since exchanging the AAs for an alanine at positions 2, 3, 4, 5, 6 or 7 
resulted in complete loss of peptide recognition. These results do not exclude the possibility of 
cross-reactivity towards other specific peptides, but it dismisses the risk of a highly promiscuous 
TCR. A search for specific human self-protein derived peptides with the motif X-I-G-E-V-L-V-
X-X did not yield any potential off-target toxicity candidates. However, when we used the 9-mer 
CPL scan data to conduct a CPL-driven search of the human self-protein database, we found 
cross-reactivity directed against a peptide derived from the gene CDH13. This was confirmed by 
the ability of the 7B5 T-cell clone to recognize HA-2
neg
 EBV-LCLs transduced with the CDH13 
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gene and a range of tissues that endogenously express CDH13 including fibroblasts, 
keratinocytes and proximal tubular epithelial cells (PTEC). 
All these results demonstrate that the 7B5 T-cell clone can activate in response to healthy HLA-
A*02:01
pos
 tissues such as fibroblasts, which is likely to have severe clinical consequences if this 
TCR was engineered into T-cells for adoptive therapy in patients. Therefore, we conclude that 
thorough validation of the specificity and characterization of cross-reactivity by combining 
several screening techniques should be a strict prerequisite for TCRs to be tested prior to their 
use in the clinic. 
The alanine scanning approach was insufficient for detecting potentially dangerous cross-
reactivities, whereas a CPL-driven search of the human self-protein database enabled the 
identification of a potentially dangerous reactivity directed towards a human self-protein derived 
epitope. In the alanine scanning approach only one AA is replaced at a time and the AAs are 
only replaced with a single AA (alanine), no other AAs with different properties. So it is no 
surprise that cross-reactivity against a peptide that differs from the MiHA peptide HA-2 in 5 AA 
positions, cannot be discovered using this assay. Because the 9-mer CPL fixes only one AA at 
one position per peptide mixture, all possible sequences (except those with more than one 
cysteine) are represented in the assay and cross-reactive peptides that differ substantially from 
the immunogenic target peptide can be identified. The downside of this approach is that every 
mixture consists of many peptides, lowering the concentration per unique peptide and increasing 
the competition for HLA-binding within every mixture. These factors might influence the results 
and could explain why for some T-cell clones that we tested with the 9-mer CPL, a sufficient 
peptide recognition signature could not be determined (data not shown). Also, the 9-mer CPL-
driven search of the human self-protein database produces such a great number of potential 
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candidates that a selection strategy is needed to keep further screening experiments manageable, 
risking unwanted exclusion of the target peptides you’re searching for. 
Although the 7B5 T-cell clone, which is derived from a HLA-mismatched setting, showed a 
potentially dangerous cross-reactivity, this does not mean that all TCRs from an allogeneic 
setting are of lesser clinical interest compared to clones derived from HLA-matched settings, e.g. 
the patient derived T-cell clone HA2.27. All TCRs have an intrinsic cross-reactive capacity
26
, 
which is necessary to cover all naturally occurring antigens that may be encountered
27
. Thus, the 
relevant question is not whether a TCR is cross-reactive, but how to predict the clinical 
consequences of this cross-reactivity
28
. Therefore, thorough screening for off-target toxicity must 
be included in the preclinical phases, to determine whether a TCR is safe for clinical application 
via adoptive transfer of TCR-engineered T-cells. To further reduce potential risks, the use of a so 
called ‘suicide switch’ could also be considered29, which enables immediate elimination of the 
transfused T-cells upon signs of toxicity. 
In summary, we demonstrate that a standard alanine scanning approach provided useful 
information about which positions in the peptide sequence are important for TCR recognition, 
but it did not predict off-target reactivity of the 7B5 TCR. However, we were able to detect off-
target reactivity directed against a peptide derived from CDH13 using a CPL-driven search of the 
human self-protein database, which was confirmed using CDH13 transduced HA-2
neg
 EBV-
LCLs and screening against several different cell subsets which endogenously express CDH13. 
This example demonstrates the advantage and need of combining several screening techniques to 
characterize the cross-reactivity and specificity of TCRs. 
 
Materials and Methods 
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Culture conditions and cells 
All studies using human material were approved by the Leiden University Medical Center ethical 
review board. Peripheral blood was obtained from healthy individuals or patients after informed 
consent. Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-gradient 
centrifugation. 
T-cells were cultured in T-cell medium consisting of IMDM (Lonza) supplemented with 100 
IU/ml IL-2 (Proleukine; Novartis Pharma), 5% fetal bovine serum (FBS; Gibco, Life 
Technologies), 5% human serum, 2 mM L-glutamine (Lonza) and 1% penicillin/streptomycin 
(Lonza). T-cells were stimulated using irradiated feeders in a 1:5 ratio in T-cell medium 
supplemented with 0.8 μg/ml phytohemagglutinin (PHA; Biochrom AG) 8-16 days prior to 
experiments. 
Epstein-Barr virus -transformed B-lymphoblastic cell lines (EBV-LCLs) were generated using 
standard procedures and cultured in IMDM supplemented with 10% FBS, 2 mM L-glutamine  
and 1% penicillin/streptomycin. 
Primary AML samples from patients at time of diagnosis were thawed and cultured overnight in 
IMDM supplemented with 10% FCS before use in experiments. 
Fibroblasts, keratinocytes and other non-hematopoietic cell subsets were cultured  either in the 
absence or presence of 200 IU/ml IFN-γ for two days and washed twice before use in 
experiments. 
 
Isolation of the HA-2 reactive T-cell clone 7B5 
To isolate HA-2 reactive T-cell clones, 500x10
6
 PBMCs from an HLA-A*02:01
neg
 healthy donor 
were incubated with PE-labeled pMHC-tetramers, composed of HA-2 9-mer peptide 
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(YIGEVLVSV) bound in HLA-A*02:01, for 1 hour at 4°C. Cells were washed twice, and 
incubated with anti-PE-microbeads (Miltenyi Biotec) for 15 minutes at 4°C. PE-labeled cells 
were isolated on an LS column (Miltenyi Biotec) according to manufacturer’s instruction. 
Positively selected cells were stained with an anti-CD8 Alexa700-labelled antibody 
(Invitrogen/Caltag) in combination with FITC-conjugated antibodies against CD4, CD14, and 
CD19 (BD Pharmingen). pMHC-tetramer
pos
 CD8
pos
 FITC
neg
 T-cells were single-cell sorted into 
round-bottom 96-well plates containing 5x10
4
 irradiated feeders in 100 μl T-cell medium 
supplemented with 0.8 μg/ml PHA for expansion. 
 
FACS analysis 
FACS acquisition was performed on a LSRII (BD Biosciences) and was analyzed using Diva 
Software (BD Biosciences). T-cell clones were analyzed for binding to the HA-2 specific APC-
labeled pMHC-tetramer, an irrelevant PE-labeled pMHC-tetramer and an Alexa700-conjugated 
antibody against CD8 (Invitrogen/Calteg). 10,000 T-cells were first incubated with 2 µg/ml 
pMHC-tetramers for 15 min at 37°C and washed, before anti-CD8 antibodies were added and 
incubated for an additional 15 min at 4°C. 
 
Functional analysis 
For analysis of IFN-γ production, 5000 T-cells were cocultured with 30,000 target cells or T2 
cells loaded with peptides in 384 well plates. Peptide loading was performed by incubating T2 
cells for 30 minutes at 37°C and 5% CO
2
. T-cells were washed twice before use. After overnight 
incubation, supernatants were harvested, and the concentration of IFN-γ was measured by 
ELISA (Sanquin Reagents). 
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To assess the peptide recognition signature we used a previously described 9-mer CPL scan
22
, 
consisting of 180 different peptide mixtures. In each peptide mixture all peptides have one fixed 
L-amino acid (AA) residue at one AA position, but all other positions are degenerate, enabling 
incorporation of any 1 of 19 natural L-amino acids in all remaining 8 positions (cysteine is 
excluded in non-fixed positions). For this assay, we pulsed 20,000 T2 cells with each of the 180 
different peptide mixtures at a concentration of 100 µM for two hours at 37°C and 5% CO
2
 in 40 
µl T-cell medium (IMDM supplemented with 100 IU/ml IL-2, 5% fetal bovine serum, 5% 
human serum, 2 mM L-glutamine and 1% penicillin/streptomycin). After peptide loading, 4000 
T-cells in 20 µl T-cell medium were added per well. After overnight incubation, supernatants 
were harvested and IFN-y production was measured by ELISA (Sanquin Reagents). 
 
Analysis of the peptide recognition signature 
To analyze the data from the 9-mer CPL scan, we used the WSBC PI CPL webtool
30
 that applies 
a mathematical strategy to match the peptide recognition signature
31
 with the human proteome to 
predict the most likely human self-protein derived peptide sequences that might be recognized by 
the tested TCR
26
. We examined 100 peptides with the best log likelihood scores and removed 
duplicate sequences. The 10 peptide sequences that were predicted to bind HLA-A*02:01, 
according to NetMHC4.0, were synthesized.  
 
Gene transduction 
The CDH13 gene was cloned into the modified MP71-retroviral backbone, together with the 
truncated nerve growth factor-receptor (NGF-R, also known as CD271). The constructs were 
transfected into Phoenix-A cells using helper vector M57 and Fugene HD reagent (Roche). Virus 
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supernatant was harvested after 48 and 72 hours and stored at -80°C. 
For transduction of EBV-LCLs, 24-well non tissue-culture plates were coated with 30 mg/ml 
retronectin (Takara) for 2 hours at room temperature and blocked with 2% human serum albumin 
(Sanquin Reagents) for 30 minutes. Viral supernatant was thawed, then 500 µl per well was 
added to the 24-well plate and spun down at 2000 G for 20 minutes at 4°C. 100,000 EBV-LCLs 
per well were added in 500 µl fresh IMDM supplemented with 10% FBS, 2 mM L-glutamine  
and 1% penicillin/streptomycin and incubated overnight at 37°C and 5% CO
2
. CDH13
pos
 EBV-
LCLs were MACS purified using anti-CD271 PE-labeled antibody (BD Pharmingen) and anti-
PE-microbeads (Miltenyi Biotec). CDH13 transduced cells were isolated on an LS column 
following manufacturer’s instructions. 
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Table 1: HLA-A*02:01 binding properties of the peptides used for the amino acid scanning 
approach. 
Sequence 
netMHC4.0 (nM; binding 
level) 
YIGEVLVSV 7.0; SB 
YIGEVLVSM 57.7; WB 
AIGEVLVSV 33.4; SB 
YAGEVLVSV 41.6; WB 
YIAEVLVSV 3.3; SB 
YIGAVLVSV 12.9; SB 
YIGEALVSV 7.6; SB 
YIGEVAVSV 14.9; SB 
YIGEVLASV 7.1; SB 
YIGEVLVAV 9.1; SB 
YIGEVLVSA 30.6; SB 
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Table 2: Selected potential cross-reactive human self-protein derived peptide targets of the 
7B5 T-cell clone. The peptides in this table are selected based on their predicted recognition by 
the 7B5 TCR according to a CPL-driven search of the human self-protein database conducted 
using the WSBC PI CPL webtool, and subsequently filtered based on their ability to bind HLA-
A*02:01 as predicted by NetMHC4.0. Peptides are ordered based on their predicted likelihood of 
recognition. 
Peptide 
number 
Peptide sequence 
AA 
difference 
netMHC4.0 (nM; 
binding level) 
Gene Protein accession 
p01 SVGSVLLTV 5 160.5; WB CDH13 NP_001207417 
p02 YIGEVLVSV - 7.0; SB MYO1G NP_149043 
p03 FVGEDLVTI 5 42.6; WB BACE2 NP_036237 
p04 YIGENILVL 5 48.7; WB ASIC1 NP_001086 
p05 TLQEVLLTV 5 11.8; SB GZMH NP_219491 
p06 FIGEVVVSV 2 8.1; SB MYO1D NP_056009 
p07 SVGEVLQSV 3 116.2; WB AKAP3 NP_006413 
p08 YIGQVLVTA 3 253.2; WB EML5 NP_899243 
p09 AQGEVQLTV 5 144.1; WB PLXNB2 NP_036533 
p10 TLGNVLVTV 4 26.7; SB EXOC1 NP_001020095 
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Legends 
 
Figure 1: The 7B5 T-cell clone exhibits similar sensitivity to HA-2 compared to clone 
HA2.27 in a peptide stimulation assay and pMHC-tetramer staining. (A) T-cell clones 7B5 
and HA2.27 (5.000/well) were cocultured with T2 cells (30.000/well) loaded with HA-2 peptide 
at different concentrations. After overnight incubation, supernatants were harvested, and the 
concentration of IFN-γ was measured by ELISA. (B) T-cell clones were analyzed for binding to 
specific APC-labeled pMHC-tetramers. Depicted dotplots are gated for CD8
pos
 lymphocytes. 
 
Figure 2: The 7B5 T-cell clone recognizes HA-2 expressing EBV-LCLs and primary AML 
samples. (A) T-cell clones 7B5 and HA2.27 (5.000/well) were cocultured with several EBV-
LCLs at a stimulator to responder (S:R) ratio of 6:1. Controls included EBV-LCLs from the 
patient (LCL MRJ, HLA-A*02:01
pos
 HA-2
pos
) and donor (LCL IZA, HLA-A*02:01
pos
 HA-2
neg
) 
we isolated T-cell clone HA2.27 from, as well as HLA-A*02:01
neg
 controls LCL-MSF and LCL-
PSU. After overnight incubation, supernatants were harvested, and the concentration of IFN-γ 
was measured by ELISA. Depicted values are the average of duplicate measurements ± SD. (B) 
T-cell clones 7B5 and HA2.27 (5.000/well) were cocultured with HLA-A*02:01
pos
 HA-2
neg
 
primary AML sample (AML1), HLA-A*02:01
pos
 HA-2
pos
 primary AML samples (AML2,-3,-4), 
and HLA-A*02:01
pos
 HA-2
neg
 fibroblasts (FB) and keratinocytes (KC) at an S:R ratio of 6:1. 
After overnight incubation, supernatants were harvested, and the concentration of IFN-γ was 
measured by ELISA. Depicted values are the average of duplicate measurements ± SD. 
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Figure 3: The alanine scanning approach for T-cell clones 7B5 and HA2.27. T-cell clones 
7B5 and HA2.27 (5.000/well) were cocultured with T2 cells (30.000/well), loaded with 8 nM 
(A), 40 nM (B) and 200 nM (C) peptides. After overnight incubation IFN- γ concentrations were 
measured in the supernatant by ELISA. Where alanine substitution resulted in a substantial 
decrease in IFN-γ production compared to the immunogenic HA-2 sequence, the residue at this 
position was considered essential. 
 
Figure 4: A heatmap representation of a 9-mer CPL scan of the 7B5 T-cell clone. A heatmap 
depicting the intensity of IFN-γ production by the 7B5 T-cell clone (4.000/well) in response to 
T2 cells (20.000/well) loaded with the 180 peptide mixtures in a 9-mer CPL scan, indicating 
which AAs are preferentially recognized at certain positions in the peptide sequence. CPL scan 
data are normalized in each row so that the values range from high (red) to low (blue); the 
maximum intensity is the largest of all red values in the rows. Amino acids are grouped 
according to their physicochemical properties as follows: polar, uncharged amines: Q, N; polar, 
uncharged alcohols: T, S; small: G, A, C; hydrophobic: A–H; aliphatic: V, I, L; aromatic: Y, F, 
W, H; large: F, W; charged basic: H, K, R; and charged acidic: E, D. 
 
Figure 5: The 7B5 T-cell clone recognizes the CDH13 derived peptide p01, whereas T-cell 
clone HA2.27 does not. T-cell clones (A) 7B5 and (B) HA2.27 (5.000/well) were cocultured 
with T2 cells (30.000) loaded with the selected peptides at different concentrations. After 
overnight incubation, supernatants were harvested, and the concentration of IFN-γ was measured 
by ELISA. Depicted values are the average of duplicate measurements ± SD. p01: Cadherin-13 
isoform 2; p02: Myosin-Ig MiHA HA-2 (V); p03: Beta-secretase 2 Isoform 4; p04: Amiloride-
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sensitive cation channel 2, neuronal isoform b; p05: Granzyme H; p06: Myosin-Id; p07: A-
kinase anchor protein 3; p08: Echinoderm microtubule-associated protein-like 5; p09: Plexin-B2 
precursor; p10: Exocyst complex component 1 isoform 1; p11: Myosin-Ig AC HA-2 (M). (C) T-
cell clone 7B5 and HA-2 control clone (5.000/well) were cocultured with HA-2
neg
 EBV-LCL 
IZA and HRK, untransduced or transduced with CDH13, at an S:R ratio of 6:1. The HA-2
pos
 
EBV-LCL MRJ was included as a positive control. After overnight incubation, supernatants 
were harvested, and the concentration of IFN-γ was measured by ELISA. Depicted values are the 
average of duplicate measurements ± SD. 
 
Figure 6: The endogenously processed CDH13 derived peptide p01, presented in HLA-
A*02:01, efficiently activates the 7B5 T-cell clone, but not T-cell clone HA2.27. T-cell clones 
7B5 and HA2.27 (5.000/well) were cocultured with different cell subsets endogenously 
expressing the CDH13 gene: keratinocytes and fibroblasts, untreated or pretreated with IFN-γ for 
2 days to upregulate HLA expression, proximal tubular epithelial cells, and melanoma cell line 
FM6. To confirm that only HLA-A*02:01 restricted epitopes are recognized, we tested the 7B5 
and HA2.27 T-cell clone also against HLA-A*02:01
neg
 fibroblasts, untreated or pretreated with 
IFN-γ. We also included the EBV-LCL controls from the patient (LCL MRJ, HLA-A*02:01pos 
HA-2
pos
) and donor (LCL IZA, HLA-A*02:01
pos
 HA-2
neg
) we isolated the HA2.27 T-cell clone 
from. After overnight incubation, supernatants were harvested, and the concentration of IFN-γ 
was measured by ELISA. Average IFN-γ production by the HA2.27 T-cell clone stimulated with 
LCL MRJ was set to 1. Depicted values are the average of duplicate measurements ± SD. 
*Single measurements. 
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Supplementary Figure 1: Gene expression profile for minor histocompatibility antigen HA-
2 (MYO1G). Probe fluorescence intensity is shown on the x-axis in logarithmic scale. On the y-
axis malignant and healthy (non-)hematopoietic cell types are shown. Each dot represents a 
different sample and the mean and standard deviation of gene expression is shown for each cell 
type. 
 
Supplementary Table 1: Potential cross-reactive human self-protein derived peptide 
targets of the 7B5 T-cell clone. The peptides in this table are selected based on their predicted 
recognition by the 7B5 T-cell clone according to a CPL-driven search of the human self-protein 
database conducted using the WSBC PI CPL webtool. 
 
Supplementary Figure 2: Gene expression profile for CDH13. Probe fluorescence intensity is 
shown on the x-axis in logarithmic scale. On the y-axis malignant and healthy (non-) 
hematopoietic cell types are shown. Each dot represents a different sample and the mean and 
standard deviation of gene expression is shown for each cell type. 
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